Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

05-26-2016 | Cardiovascular disorders | Review | Article

Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?

Journal: Endocrine

Authors: Maria Ida Maiorino, Giuseppe Bellastella, Dario Giugliano, Katherine Esposito

Publisher: Springer US

Login to get access

Abstract

Chronic inflammation is supposed to be an important mediator of cardiometabolic dysfunctions seen in type 2 diabetes. In this mini-review, we collected evidence (PubMed) from randomized controlled trials (through March 2016) evaluating the effect of anti-inflammatory drugs on indices of glycemic control and/or cardiovascular events in people with type 2 diabetes. Within the last 25 years, many anti-inflammatory drugs have been tested in type 2 diabetes, including hydroxychloroquine, anti-tumor necrosis factor therapies (etanercept and infliximab), salsalate, interleukin-1 antagonists (anakinra, canakinumab, gevokizumab, LY2189102), and CC-R2 antagonists. Despite being promising, the observed effects on HbA1c or glucose control remain rather modest in most clinical trials, especially with the new drugs. There are many trials underway with anti-inflammatory agents to see whether patients with cardiovascular diseases and/or type 2 diabetes may have clinical benefit from marked reductions in circulating inflammatory markers. Until now, a large trial with losmapimod (a p38 inhibitor) among patients with acute myocardial infarction, including one/third of diabetic patients, showed no reduction in the risk of major ischemic cardiovascular events. Further evidence is warranted in support of the concept that targeting inflammation pathways may ameliorate glycemic control and also reduce cardiovascular complications in type 2 diabetes.
Literature
1.
G.S. Hotamisligil, N.S. Shargill, B.M. Spiegelman, Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87–91 (1993)CrossRefPubMed
2.
G.S. Hotamisligil, A. Budavari, D. Murray, B.M. Spiegelman, Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-alpha. J. Clin. Investig. 94, 1543–1549 (1994)CrossRefPubMedPubMedCentral
3.
P. Libby, Inflammation in atherosclerosis. Nature 420, 868–874 (2002)CrossRefPubMed
4.
K. Esposito, D. Giugliano, The metabolic syndrome and inflammation: association or causation? Nutr. Metab. Cardiovasc. Dis. 14, 228–232 (2004)CrossRefPubMed
5.
C. Belizna, Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun. Rev. 14, 358–362 (2015)CrossRefPubMed
6.
Y.C Kaplan, J. Ozsarfati, C. Nickel, G. Koren, Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. (2015 Dec 23). doi: 10.​1111/​bcp.​12872. [Epub ahead of print]
7.
A. Quatraro, G. Consoli, M. Magno et al., Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann. Intern. Med. 112, 678–681 (1990)CrossRefPubMed
8.
H.C. Gerstein, K.E. Thorpe, D.W. Taylor, R.B. Haynes, The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas—a randomized trial. Diabetes Res. Clin. Pract. 55, 209–219 (2002)CrossRefPubMed
9.
A. Pareek, N. Chandurkar, N. Thomas et al., Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr. Med. Res. Opin. 30, 1257–1266 (2014)CrossRefPubMed
10.
M.C. Wasko, H.B. Hubert, V.B. Lingala, J.R. Elliott, M.E. Luggen, J.F. Fries, M. Ward, Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298, 187–193 (2007)CrossRefPubMed
11.
T.S. Sharma, M.C. Wasko, X. Tang, D. Vedamurthy, X. Yan, J. Cote, A. Bili, Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J. Am. Heart. Assoc. 4, 5 (2016)
12.
M.A. Gonzalez-Gay, C. Gonzalez-Juanatey, T.R. Vazquez-Rodriguez et al., Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann. N. Y. Acad. Sci. 1193, 153–159 (2010)CrossRefPubMed
13.
J. Channual, J.J. Wu, F.J. Dann, Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol. Ther. 22, 61–73 (2009)CrossRefPubMed
14.
E. Parmentier-Decrucq, A. Duhamel, O. Ernst et al., Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn’s disease. Inflamm. Bowel Dis. 15, 1476–1484 (2009)CrossRefPubMed
15.
F. Ofei, S. Hurel, J. Newkirk, M. Sopwith, R. Taylor, Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45, 881–885 (1996)CrossRefPubMed
16.
H. Dominguez, H. Storgaard, C. Rask-Madsen et al., Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 42, 517–525 (2005)CrossRefPubMed
17.
N. Esser, N. Paquot, A.J. Scheen, Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin. Investig. Drugs 24, 283–307 (2015)CrossRefPubMed
18.
Q. Javed, I. Murtaza, Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ. 22, 323–327 (2013)CrossRefPubMed
19.
J. Zhang, F. Xie, H. Yun, et al, Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann. Rheum. Dis. (2016 Jan 20). doi: 10.​1136/​annrheumdis-2015-207870. [Epub ahead of print]
20.
S.E. Shoelson, J. Lee, A.B. Goldfine, Inflammation and insulin resistance. J. Clin. Investig. 116, 1793–1801 (2006)CrossRefPubMedPubMedCentral
21.
M.J. Yin, Y. Yamamoto, R.B. Gaynor, The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396, 77–80 (1998)CrossRefPubMed
22.
T.D. Gilmore, Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25, 6680–6684 (2006)CrossRefPubMed
23.
A.B. Goldfine, V. Fonseca, K.A. Jablonski, L. Pyle, M.A. Staten, S.E. Shoelson, TINSAL-T2D (TargetingInflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 152, 346–357 (2010)CrossRefPubMedPubMedCentral
24.
A.B. Goldfine, V. Fonseca, K.A. Jablonski, Y.D. Chen, L. Tipton, M.A. Staten, S.E. Shoelson, Targeting inflammation using salsalate in type 2 diabetes study team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 159, 1–12 (2013)CrossRefPubMedPubMedCentral
25.
A.B. Goldfine, J.S. Buck, C. Desouza et al., Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care 36, 4132–4139 (2013)CrossRefPubMedPubMedCentral
26.
K. Maedler, P. Sergeev, F. Ris et al., Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Investig. 110, 851–860 (2002)CrossRefPubMedPubMedCentral
27.
C.M. Larsen, M. Faulenbach, A. Vaag, A. Vølund, J.A. Ehses, B. Seifert, T. Mandrup-Poulsen, M.Y. Donath, Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517–1526 (2007)CrossRefPubMed
28.
C. Herder, E. Dalmas, M. Böni-Schnetzler, M.Y. Donath, The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol. Metab. 26, 551–563 (2015)CrossRefPubMed
29.
H.J. Lachmann, I. Kone-Paut, J.B. Kuemmerle-Deschner, K.S. Leslie, E. Hachulla, P. Quartier, X. Gitton, A. Widmer, N. Patel, P.N. Hawkins, Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416–2425 (2009)CrossRefPubMed
30.
P.M. Ridker, C.P. Howard, V. Walter, on behalf of the CANTOS Pilot Investigative Group et al., Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen. A phase IIb randomized, placebo-controlled trial. Circulation 126, 2739–2748 (2012)CrossRefPubMed
31.
C. Cavelti-Weder, A. Babians-Brunner, C. Keller, M.A. Stahel, M. Kurz-Levin, H. Zayed, A.M. Solinger, T. Mandrup-Poulsen, C.A. Dinarello, M.Y. Donath, Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35, 1654–1662 (2012)CrossRefPubMedPubMedCentral
32.
J. Sloan-Lancaster, E. Abu-Raddad, J. Polzer, J.W. Miller, J.C. Scherer, A. De Gaetano, J.K. Berg, W.H. Landschulz, Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239–2246 (2013)CrossRefPubMedPubMedCentral
33.
N.A. Di Prospero, E. Artis, P. Andrade-Gordon, D.L. Johnson, N. Vaccaro, L. Xi, P. Rothenberg, CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Diabetes Obes. Metab. 16, 1055–1064 (2014)CrossRefPubMed
34.
S. Kaptoge, E. Di Angelantonio, G. Lowe, M.B. Pepys, S.G. Thompson, R. Collins, J. Danesh, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132–140 (2010)CrossRefPubMed
35.
P.M. Ridker, T. Thuren, A. Zalewski, P. Libby, Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597–605 (2011)CrossRefPubMed
36.
P.M. Ridker, Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J. Thromb. Haemost. 7(Suppl 1), 332–339 (2009)CrossRefPubMed
37.
P.M. Ridker, T.F. Lüscher, Anti-inflammatory therapies for cardiovascular disease. Eur. Heart J. 35, 1782–1791 (2014)CrossRefPubMedPubMedCentral
38.
M.L. O’Donoghue, R. Glaser, M.A. Cavender, LATITUDE-TIMI 60 Investigators et al., Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA 315, 1591–1599 (2016)CrossRefPubMed
39.
L.K. Newby, M.S. Marber, C. Melloni et al., SOLSTICE investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 384, 1187–1195 (2014)CrossRefPubMed
40.
M.Y. Donath, Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia 59, 679–682 (2016)CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Image Credits